Wealth Manager Sells $7 Million of Establishment Labs After Massive Gains. Is This Medical Device Stock a Buy?

1 week ago 21

Kris Eddy, The Motley Fool

Sat, May 30, 2026 astatine 3:19 PM CDT 4 min read

On May 15, 2026, Rice Hall James & Associates reported selling 102,885 shares of Establishment Labs (NASDAQ:ESTA), an estimated $7.03 cardinal transaction based connected quarterly mean pricing.

What happened

According to the SEC filing dated May 15, 2026, Rice Hall James & Associates reduced its presumption successful Establishment Labs by 102,885 shares during the archetypal quarter. The estimated worth of shares sold was $7.03 million, calculated utilizing the mean closing terms for the period. At quarter-end, the money held 548,674 ESTA shares, valued astatine $31.15 million.

What other to cognize

The merchantability brought the ESTA presumption to 1.73% of reportable assets nether management
Top holdings aft the filing:
- NASDAQ: LGND: $56.61 cardinal (3.2% of AUM)
- NYSE: FN: $55.18 cardinal (3.1% of AUM)
- NYSE: ARLO: $52.08 cardinal (2.9% of AUM)
- NYSE: XPO: $43.64 cardinal (2.4% of AUM)
- NASDAQ: ACIW: $41.15 cardinal (2.3% of AUM)
As of May 14, 2026, ESTA shares were priced astatine $69.80, up 91.4% implicit the past year, outperforming the S&P 500 by 64.1 percent points

Company overview

Metric

Value

Price (as of marketplace adjacent May 14, 2026)	$69.80
Market capitalization	$1.93 billion
Revenue (TTM)	$229.58 million
Net income (TTM)	($43.74 million)

Company snapshot

Manufactures and markets silicone gel-filled bosom implants and related aesculapian devices, chiefly nether the Motiva Implants brand, arsenic good arsenic insubstantial expanders and autologous insubstantial processing products.
Generates gross done nonstop income and exclusive organisation agreements targeting aesthetic and reconstructive integrative country markets globally.
Serves integrative surgeons and healthcare providers successful Europe, Latin America, the Asia-Pacific region, and different planetary markets.

Establishment Labs is simply a planetary aesculapian exertion institution specializing successful precocious bosom implant solutions and related products for aesthetic and reconstructive surgery. With a absorption connected innovation and safety, it leverages proprietary technologies and planetary organisation to code the needs of integrative surgeons and their patients. Its diversified merchandise portfolio and expanding planetary beingness presumption it arsenic a competitory subordinate successful the aesculapian devices sector.

What this transaction means for investors

Establishment Labs is unprofitable but increasing rapidly, with gross expanding and caller minimally invasive technologies gaining adoption successful the expanding aesthetic country market. The banal has surged astir 100% implicit the past year, truthful this determination by Rice Hall James looks similar profit-taking.

For investors, Establishment Labs represents a classical maturation play: a mid-cap aesculapian instrumentality institution betting connected beardown request for procedures and planetary expansion. The minimally invasive concern is expected to lend importantly to gross maturation successful 2026, perchance improving profitability implicit time.

Read Entire Article